Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: John Metcalf who wrote (179)	2/7/1998 9:43:00 AM
From: ahhaha	Read Replies (1) \| Respond to of 399

A rising tide raises all boats and makes any management look terrific. With average management the company easily would have achieved 120 which would be commensurate price action relative to all the other similar companies in its group. Bio-molecular science is oxymoron. Operating independently doesn't exclude external input. You are mixing bio-pseudo-science and business operations, a deadly mistake in this business, and doubly deadly in science. When GLX starts down suddenly all those compounded investors will want to know all about the committee of monkeys because they'll need names and addresses for class action.